Pfizer is a US drug maker who has released late-stage human trails data of the Covid-19 vaccine that has been developed with German biotech Firm BioNTech. Pfizer and BioNtech has announced their mRNA-based vaccine candidate, BNT162B2, against SARS-CoV-2 has shown evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.
According to the study based on the trials found split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy which is above 90%. The efficacy rate 90% is after the second dose. This consist 2-dose schedule and its given within the duration of 28 days.
“Today is a great day for science and humanity. The first set of results from our Phase3 COVID=19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” Said Dr.Albert Bourla, Pfizer Chairman and CEO in a statement released upon the results
“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a global collaborative effort,” Prof Ugur Sahin ,BioNTech ,Co-Founder and CEO in a statement released upon the results
Environmental toxins, including pesticides, heavy metals, and industrial pollutants, are increasingly being recognized as significant…
The recent issue of expired IV fluids being used in healthcare settings has raised alarms…
Mahakumbh 2025: A tragic incident occurred at Mahakumbh 2025, where three people, including a sadhu,…
Sickle Cell Disease: Sickle Cell Disease is a serious health issue that particularly affects the…
Kerala Is Facing Low Birth rate: Kerala is facing a significant decline in its birth…
Hypertension, or high blood pressure, has become a silent but deadly crisis in India. The…